Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients.
Kasikova L, Hensler M, Truxova I, Skapa P, Laco J, Belicova L, Praznovec I, Vosahlikova S, Halaska MJ, Brtnicky T, Rob L, Presl J, Kostun J, Cremer I, Ryska A, Kroemer G, Galluzzi L, Spisek R, Fucikova J. Kasikova L, et al. Among authors: kostun j. J Immunother Cancer. 2019 Nov 20;7(1):312. doi: 10.1186/s40425-019-0781-z. J Immunother Cancer. 2019. PMID: 31747968 Free PMC article.
Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.
Ptáková N, Miesbauerová M, Kosťun J, Grossmann P, Šidlová H, Pavelka J, Presl J, Alaghehbandan R, Bouda J, Ondič O. Ptáková N, et al. Among authors: kostun j. Virchows Arch. 2018 Nov;473(5):583-590. doi: 10.1007/s00428-018-2428-8. Epub 2018 Aug 16. Virchows Arch. 2018. PMID: 30116888
Molecular substratification of endometrial carcinomas with no special molecular profile (NSMP) by using a limited NGS custom panel may facilitate effective patient selection for the PIK3CA-targeted therapy.
Ondič O, Michalová K, Švajdler M, Presl J, Kosťun J, Hájková V, Martínek P, Michal M. Ondič O, et al. Among authors: kostun j. Virchows Arch. 2024 Sep 5. doi: 10.1007/s00428-024-03905-6. Online ahead of print. Virchows Arch. 2024. PMID: 39235514
22 results